Abstract | UNLABELLED: METHODS: Twenty-two patients (age, 70 ± 12 y) admitted to the coronary care unit with AIHF underwent nicorandil-stress and rest myocardial perfusion SPECT. Using these images, MBR-IR was calculated by dividing stress MBR by rest MBR (MBR = peak value of left ventricular myocardial segments/mean value of upper mediastinum). In order to evaluate the clinical importance of MBR-IR derived from the nicorandil-stress test, all patients were divided into 2 groups, based on the value of MBR-IR. All patients were observed over 5 y from the onset of AIHF for the occurrence of major adverse cardiac events ( MACE). RESULTS: Both high- and low-MBR-IR groups contained 11 participants. Median MBR-IR was 1.55 (1.34-1.61) in the high-MBR-IR group and 1.08 (1.02-1.10) in the low-MBR-IR group. The proportion of patients who experienced MACE was significantly higher in the low-MBR-IR group than in the high-MBR-IR group (91% vs. 18%, P < 0.001). CONCLUSION: This study demonstrated that the MBR-IR calculated using nicorandil-stress myocardial perfusion SPECT may have a high prognostic value for MACE in patients with AIHF.
|
Authors | Yoshimitsu Fukushima, Shin-ichiro Kumita, Yukichi Tokita, Naoki Sato |
Journal | Journal of nuclear medicine : official publication, Society of Nuclear Medicine
(J Nucl Med)
Vol. 57
Issue 3
Pg. 385-91
(Mar 2016)
ISSN: 1535-5667 [Electronic] United States |
PMID | 26635345
(Publication Type: Case Reports, Journal Article)
|
Copyright | © 2016 by the Society of Nuclear Medicine and Molecular Imaging, Inc. |
Chemical References |
- Vasodilator Agents
- Nicorandil
|
Topics |
- Aged
- Aged, 80 and over
- Exercise Test
- Female
- Heart
(diagnostic imaging)
- Heart Failure
(diagnostic imaging)
- Humans
- Kaplan-Meier Estimate
- Male
- Myocardial Ischemia
(diagnostic imaging)
- Myocardial Perfusion Imaging
- Myocardium
(metabolism)
- Nicorandil
(administration & dosage, pharmacokinetics)
- Positron-Emission Tomography
- Prognosis
- Rest
- Risk Factors
- Tomography, Emission-Computed, Single-Photon
- Vasodilator Agents
(administration & dosage, pharmacokinetics)
|